Perjeta + trastuzumab in early HER2‑positive breast cancer delivers a 1.8% absolute overall‑survival benefit at 10 years — and only in high risk node‑positive patients.
That means 100 people get a year of dual‑antibody toxicity, so that 2 benefit over ten years. This result was just barely statistically significant, and only in a subgroup that represents about third of the overall EBC population.

And the price tag?
Roughly $90,000 per patient and $450k per life saved.

After a ten year followup on a trial designed by pharma from the ground up to deliver a positive result.

Given the marketing and the broad FDA approval, I wonder how many of those 100,000 patients treated were actually high risk node positive.

Yes, biosimilars are finally approved.

But let’s be honest: the system is financially structured to protect originator margins, not accelerate biosimilar adoption. Watch how slowly the “cost‑savings” narrative moves when revenue is on the line.

Data matters. Incentives matter even more.

#HER2 #BreastCancer hashtag #Oncology #HealthEconomics #Biosimilars #ValueBasedCare #EvidenceBasedMedicine #HealthcareCosts #Pharma #ClinicalTrials

Originally published by Bhargav Raman, MD
Cofounder, Clinical Strategy and Analytics
https://www.linkedin.com/posts/universalistmd_her2-breastcancer-oncology-activity-7419385778037813249-9CNm/